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Peripheral tolerance to tumor antigens (Ags) is
a major hurdle for antitumor immunity. Draining
lymph nodes are considered the privileged sites for
Ag presentation to T cells and for the onset of periph-
eral tolerance. Here, we show that the spleen is
fundamentally important for tumor-induced toler-
ance. Splenectomy restores lymphocyte function
and induces tumor regression when coupled with
immunotherapy. Splenic CD11b+Gr-1intLy6Chi cells,
mostly comprising proliferating CCR2+-inflammatory
monocytes with features of myeloid progenitors,
expand in the marginal zone of the spleen. Here,
they alter the normal tissue cytoarchitecture and
closely associate with memory CD8+ T cells, cross-
presenting tumor Ags and causing their tolerization.
Because of its high proliferative potential, this
myeloid cell subset is also susceptible to low-dose
chemotherapy, which can be exploited as an adju-
vant to passive immunotherapy. CCL2 serum levels
in cancer patients are directly related to the accumu-
lation of immature myeloid cells and are predictive
for overall survival in patients who develop a multi-
peptide response to cancer vaccines.INTRODUCTION
The interaction between the immune system and transformed
cells can result in the elimination of developing tumors,
establishment of a growth dormancy state, or selection of
neoplastic clones with the ability to survive in immune-compe-
tent hosts (Schreiber et al., 2011). On the other hand, cells of
both innate and adaptive immunity can promote initial steps
of cancer progression by fueling chronic inflammation in the628 Cell Reports 2, 628–639, September 27, 2012 ª2012 The Authortumor microenvironment (Grivennikov et al., 2010). Most exper-
imental tumor models, as well as clinically diagnosed tumors,
are analyzed when malignant cells may have already escaped
early immune surveillance by both cell-autonomous and cell-
independent mechanisms. At this stage, the almost universal
feature of successfully progressive cancers is the activation
of abnormal myelopoiesis and the recruitment of immature
CD11b+Gr-1+ myeloid cells into different tissues (Gabrilovich
et al., 2012). This process is governed by tumor-released
soluble factors and is dependent upon upregulation of key
transcription factors in myeloid cells, such as cEBPb (Marigo
et al., 2010; Sonda et al., 2011). Myelopoiesis during acute
infections, stress, or trauma results in rapid terminal differenti-
ation of myeloid cells. In contrast, cancer myelopoiesis is asso-
ciated with defective cell differentiation, leading to the accumu-
lation and persistence of immature CD11b+Gr-1+ myeloid
elements (Gabrilovich and Nagaraj, 2009; Gabrilovich et al.,
2012; Sica and Bronte, 2007). These cells can also cause
profound alterations of antitumor immune responses. In fact,
tumors bring on a progressive tolerance toward tumor antigens
(Ags) among peripheral CD8+ T cells, which is orchestrated by
the expansion of CD11b+Gr-1+ cells (Dolcetti et al., 2010b;
Kusmartsev et al., 2005; Nagaraj et al., 2007). The current
view points toward the lymph node as the primary site for
tumor Ag presentation and tolerance induction (Nagaraj et al.,
2007), but accumulation of immature myeloid cells is extremely
limited in these secondary lymphoid organs compared with
other organs, such as the spleen. Although it was neglected
for many years, the spleen is the main lymphoid organ that
undergoes myeloid cell expansion during tumor development,
and was recently found to possess unique biological proper-
ties. The spleen accumulates monocyte and granulocyte pre-
cursors that directly replenish tumor-associated macrophages
and neutrophils during lung cancer development (Cortez-Reta-
mozo et al., 2012). Moreover, the cords of the splenic subcap-
sular red pulp contain a reservoir of a peculiar monocyte subset
that is promptly released in the bloodstream following acute
injury (Swirski et al., 2009).s
Figure 1. The Spleen Is a Key Organ for Tumor-Induced Tolerance
(A) C57BL/6mice were either injected with 106 EG7 cells or not injected. After 7 days they received i.v. 53 106 naı¨ve CD8+ T cells isolated from the spleen of OT-1
mice. After 2 days the mice were vaccinated with OVA257-264 peptide-pulsed DCs, and 5 days after vaccination, tumor-draining lymph nodes (black bar) and
spleens (white bar) were removed, stimulated with either OVA peptide or unrelated peptide, and tested for IFN-g production (ELISpot assay, left panel; intra-
cellular staining, right panel). Data are presented as the difference in IFN-g level (either as number of spots or percentage of cells) between OVA-peptide
stimulation (specific stimulation) and b-gal peptide stimulation (unspecific stimulation). Data for intracellular stainings are presented as mean ± SD of the
percentage of IFN-g-producing CD8+CD45.1+ cells, from two independent experiments (n = 6 mice/group for each experiment). Statistical analysis was per-
formed with Student’s t test.
(B) C57BL/6 mice were splenectomized or subject to sham surgery. After 14 days, mice were either injected with 106 EG7 cells or not injected. Seven days after
tumor challenge, themice received i.v. 53 106 naı¨ve CD8+ T cells isolated from the spleen of OT-1mice. After 7 days, themice were sacrificed and tumor-draining
lymph node cells were tested as in (A). Data are represented as mean ± SD of three experiments (n = 5 mice/group for each experiment). Statistical analysis was
performed with Student’s t test.
(C) When the tumor mass reached 1,000 mm3, bone marrow, tumor, liver, and blood were collected and single-cell suspensions were analyzed for CD11b+Gr-1+
cell accumulation (left panel). CD11b+ cells were immunomagnetically sorted from the same compartments and added in 1:2 serial dilutions (24% to 3% of the
effector cells) to an MLPC to test their suppressive properties (right panel). The percentage of L.U.30 of cultures containing 6% CD11b
+ cells is reported as the
mean ± SD of two independent experiments. Data were normalized on the average value of L.U.30 of MLPCs without CD11b
+ cells.
(D) Mice were either splenectomized or subjected to sham surgery. After 14 days, the mice were injected with 106 EG7 thymoma cells or not injected, and 7 days
after tumor challenge themice received i.v. 53 106 naı¨ve CD8+ T cells isolated from the spleen of OT-1mice. A Kaplan-Meier survival analysis (n = 10mice/group)
was performed to compare splenectomy versus sham-surgery groups in the absence (left panel) and presence (right panel) of ACT.
See also Figure S1.RESULTS
The Spleen Is Essential for Tumor-Induced Tolerance
We adoptively transferred naı¨ve CD8+ T cells from OT-1 mice
bearing a T cell receptor specific for ovalbumin (OVA) and traced
them in vivo using the congenic marker CD45.1. When we tested
the ex vivo activation of peripheral OVA-specific CD8+ T cells in
mice bearing a tumor expressing the OVA model tumor Ag, we
found that splenic lymphocytes, similarly to those taken from
the lymph nodes, underwent Ag-specific tolerance (Figure 1A).
Moreover, this state could not be reversed by in vivo immuniza-
tion with the same tumor Ag delivered by dendritic cells (DCs) inCela proper immune-stimulating context (Figure 1A). Therefore, we
further investigated the role of the spleen in tumor-induced toler-
ance by performing the same type of tolerance assay in either
splenectomized or sham-surgery-treated mice. Splenectomy
completely restored lymphocyte activation by tumor Ag in
tumor-draining lymph nodes (Figure 1B), and this effect could
be readily observed even when OT-1 lymphocytes were stimu-
lated in vitro with the OVA peptide before the adoptive transfer,
or in vivo following vaccination with peptide-pulsed DCs (Figures
S1A and S1B). The same results were obtained in mice from
another strain, BALB/c, bearing 4T1 mammary carcinoma ex-
pressing influenza hemagglutinin (HA) model Ag (Figure S1C).l Reports 2, 628–639, September 27, 2012 ª2012 The Authors 629
Of interest, splenectomy did not alter the distribution and
suppressive function of CD11b+Gr-1+ myeloid cells in other
tissues and blood, in at least three tumor models of different
histology (Figure 1C; the results in EG7-bearing mice are shown
here, but identical findings were obtained with MCA203 fibrosar-
coma and LLC carcinoma, not shown). In contrast to a recent
report (Cortez-Retamozo et al., 2012), splenectomy did not
affect the rate of tumor growth in our models (Figure 1D, left
panel); however, adoptive cell transfer (ACT) of tumor Ag-
specific CD8+ T cells in splenectomized mice led to a significant
increase in survival compared with mice subjected to sham
surgery (Figure 1D, right panel), further highlighting the impor-
tance of the splenic compartment in the systemic tolerization
of CD8+ T lymphocytes. These results strongly suggest that
CD8+ T cells in tumor-bearing mice go through a fundamental
step for their inactivation in the spleen, and point to splenic
CD11b+Gr-1+ cells as potential tolerogenic effectors.
Chemotherapy Increases the Efficacy of ACT by
Eliminating Splenic CD11b+Gr-1int Cells
Chemotherapy can enhance the antitumor efficacy of ACT by
several mechanisms, including the elimination of myeloid cells
(reviewed in Gabrilovich et al., 2012; Ma et al., 2010; Restifo
et al., 2012). To mimic experimentally the effect of splenectomy,
we evaluated a large panel of conventional chemotherapeutic
drugs for their ability to affect splenic CD11b+Gr-1+ cells and
restore immune competence. We previously showed that the
suppressive environment created by tumors does not allow the
generation of Ag-specific cytotoxic T lymphocytes (CTLs) in
alloantigen-stimulated cultures (mixed leukocyte culture [MLC])
set up with splenocytes of tumor-bearing mice (Bronte et al.,
1998, 1999). In this initial screening, chemotherapy doses were
selected as the lowest effective amount that did not affect tumor
growth (Figure S2A). After low-dose chemotherapy, the func-
tional rescue of allogeneic CTLs was achieved with some but
not all of the tested drugs, and it was always paralleled by a sig-
nificant decrease in the CD11b+Gr-1int cell population. In the
same mice, CD11b+Gr-1hi and CD11b+Gr-1lo cell subsets were
either poorly or not affected (Figures S2B and S2C). Moreover,
all of the drugs that reestablished CTL function also rescued
the percentages of CD3+CD8+ T cells in the spleen of tumor-
bearing mice to the levels present in tumor-free mice, whereas
the effects on CD3+CD4+ T cells were more drug dependent
(Figure S2D).
Given the relationship between the depletion of the CD11b+
Gr-1int cells subset and the recovery of CTL function, we evalu-
ated whether the elimination of this cell subset could improve the
efficacy of passive immunotherapy. To use a clinically relevant
target, we employed a protocol based on the transfer of oligoclo-
nal CTLs that recognize mouse telomerase (mTERT) Ag (Ugel
et al., 2010), in combination with different chemotherapeutic
agents.We employed two drugs that in our preliminary screening
depleted splenic CD11b+Gr-1int cells and recovered CTL func-
tion (gemcitabine and 5-fluorouracil [5-FU]), and one drug that
lacked these properties (docetaxel). The adoptive transfer of
mTERT-specific CTLs in MCA203 fibrosarcoma-bearing mice
had no effect on tumor regression unless it was preceded by
treatment with either gemcitabine or 5-FU, but not with doce-630 Cell Reports 2, 628–639, September 27, 2012 ª2012 The Authortaxel (Figure 2A). All of these drugs, whether given alone or in
combination with CTLs recognizing an irrelevant Ag, had no
impact on either tumor growth ormouse survival. From the group
of tested drugs, we selected 5-FU for further studies. For 40
years, this pyrimidine analog has been adopted for the
clinical treatment of various solid tumors, and particularly for
breast cancer and gastrointestinal malignancies. Moreover,
5-FU does not cause immunogenic cancer-cell death of tumor
cells (Vincent et al., 2010), which allowed us to focus on its
effect on immune cells. To rule out the contribution of regulatory
T lymphocytes and cytokine sinks operated by competing T
lymphocytes and NK cells (Gattinoni et al., 2006) as a possible
explanation for the immune benefits of 5-FU, we also tested
the combinatorial therapy in immunodeficient Rag2/gc
/
mice. A prolongation of mouse overall survival (OS) by a single
inoculation of 5-FU before mTERT-specific ACT was observed
in two different tumor models in Rag2/gc
/ mice (Figure 2B).
Tomaximize the adjuvant activity of chemotherapy, we exploited
a schedule consisting of repeated administration of 5-FU in
combination with mTERT-based ACT. In both immunocom-
petent and immunodeficient mouse strains, the growth of
MCA203 tumor was controlled, resulting in prolonged survival
for all of the treated mice (Figure 2C). No toxic side effects
were recorded in the cohorts of mice during the duration of the
treatment.
To verify that splenic CD11b+Gr-1int cells critically contributed
to limit ACT efficacy, we isolated CD11b+Gr-1hi and CD11b+
Gr-1int cells from the spleen of Rag2/gc
/ tumor-bearing
mice and transferred them into Rag2/gc
/ tumor-bearing
recipients that had received 5-FU 2 days earlier. The next day,
the mice were adoptively transferred with mTERT-specific
CTLs. Reconstitution with CD11b+Gr-1int cells, but not CD11b+
Gr-1hi cells, abrogated the 5-FU immune adjuvant activity (Fig-
ure 2D), suggesting that this specific myeloid cell subset is crit-
ical for the impairment of antitumor immunity.
CD11b+Gr-1int Splenocytes Comprise Cycling,
Committed Precursors that Resemble Inflammatory
Monocytes
When we analyzed the kinetics of myeloid repopulation in the
spleen of tumor-bearing mice following exposure to either
control vehicle or 5-FU, we found that all the myeloid subsets
were initially affected by chemotherapy (Figure 3A), as expected.
However, after administration of a single dose of 5-FU, CD11b+
Gr-1hi and CD11b+Gr-1lo cells reached the numbers of untreated
tumor-bearing mice in 30 days, whereas this did not occur for
CD11b+Gr-1int cells. The effect of 5-FU on CD11b+Gr-1int cells
was indeed long-lasting, as in treated mice this cell subset was
still 15% of its counterpart in untreated control mice.
We also quantified the proliferative rate of different myeloid
subsets in vivo by estimating the percentage of bromodeoxyur-
idine (BrdU)-incorporating cells after a 48 hr pulse with this
synthetic nucleoside. While CD11b+Gr-1hi cells in the bone
marrow were cycling, the same cell population was not prolifer-
ating in the spleen of tumor-free and tumor-bearing mice. On the
contrary, CD11b+Gr-1int and CD11b+Gr-1lo cells were prolifer-
ating in the spleen and bone marrow of tumor-free mice, and
when the tumor was present, the percentage of BrdU+ cellss
Figure 2. Adjuvant Activity of Low-Dose Chemotherapy on Adoptive Immunotherapy
(A) Therapeutic effectiveness of a single combination of chemotherapy and ACTwithmTERT198-205 CTLs. C57BL/6micewere injectedwith 10
6MCA203 sarcoma
cells in the right flank. When tumor volume was 200 mm3, mice were treated with a single i.p. injection of either 5-FU (40 mg/kg), gemcitabine (120 mg/kg),
or docetaxel (10 mg/kg). After 3 days, mice received 5 3 106 CTLs i.v. Mice were sacrificed when tumor volume reached 1,000 mm3. Survival data for
one representative experiment (n = 10 for each group) are shown. Kaplan-Meier survival analysis: mTERT198-205 CTLs versus b-gal96-103 CTLs, p = 0.558;
mTERT198-205 CTLs versus gemcitabine, p = 0.476; mTERT198-205 CTLs versus docetaxel, p = 0.998; mTERT198-205 CTLs versus 5-FU, p = 0.999; mTERT198-205
CTLs versus mTERT198-205 CTLs + gemcitabine, p = 0.0002; mTERT198-205 CTLs versus mTERT198-205 CTLs + docetaxel, p = 0.998; mTERT198-205 CTLs versus
mTERT198-205 CTLs + 5-FU, p = 0.0002; mTERT198-205 CTLs + 5-FU versus mTERT198-205 CTLs + docetaxel, p = 0.0002; and mTERT198-205 CTLs + 5-FU versus
mTERT198-205 CTLs + gemcitabine, p = 0.996.
(B) Therapeutic effectiveness of a single combination of 5-FU injection and ACT with mTERT198-205 CTLs in different tumor models. Rag2
/gc
/mice were s.c.
implanted with 106 of either TC-1 lung carcinoma orMCA203 sarcoma cells in the right flank.When tumor volumewas200mm3,mice were treated as described
in (A). Cumulative data from three separate experiments (n = 15/group) are shown. Kaplan-Meier survival analysis in MCA203 model: mTERT198-205 CTLs versus
b-gal96-103 CTLs, p = 0.0031; mTERT198-205 CTLs versus 5-FU, p = 0.0028; and mTERT198-205 CTLs versus mTERT198-205 CTLs + 5-FU, p = 0.0008.
Mantel-Haenszel statistic analysis in TC-1 model: mTERT198-205 CTLs versus b-gal96-103 CTLs, p = 0.0049; mTERT198-205 CTLs versus 5-FU, p = 0.0047; and
mTERT198-205 CTLs versus 5-FU + mTERT198-205 CTLs, p = 0.0017.
(C) Therapeutic effectiveness of repeated combination of ACT and 5-FU every 15 days. Rag-2/gc
/mice (left panel) and C57BL/6 mice (right panel) were
implanted withMCA203 sarcoma cells and treatedwith 5-FU as described in (A). After 3 days,mice received ACT. Treatment was repeated on days 15, 30, and 45
following the first ACT. A survival plot derived from three separate experiments (n = 15 for each group) is shown. Kaplan-Meier survival analysis for Rag2/gc
/
model: 5-FU + mTERT198-205 CTLs versus 5-FU + b-gal96-103 CTLs, p = 0.000012. Kaplan-Meier survival analysis for C57BL/6 mice model: 5-FU + mTERT198-205
CTLs versus 5-FU + b-gal96-103 CTLs, p = 0.000036.
(D) Rag2/gc
/mice were implanted with MCA203 sarcoma cells and treated with 5-FU as described in (A). After 2 days, 5 3 106 CD11b+Gr-1int or CD11b+
Gr-1hi cells, isolated from the spleen of MCA203 tumor-bearing Rag2/gc
/mice, were injected i.v. After 1 day, mice received mTERT198-205 CTLs. A survival
plot of one representative experiment (n = 6 for each group) is shown.Mantel-Haenszel statistic analysis: 5-FU +mTERT198-205 CTLs versus 5-FU +mTERT198-205
CTLs + CD11b+Gr-1int, p = 0.000557; 5-FU + mTERT198-205 CTLs + CD11b
+Gr-1int versus 5-FU + mTERT198-205 CTLs + CD11b
+Gr-1hi, p = 0.000568; and 5-FU +
mTERT198-205 CTLs versus 5-FU + mTERT198-205 CTLs + CD11b
+Gr-1hi, p = 0.490.
See also Figure S2.increased in the spleen but not in the bone marrow (Figure 3B,
left panel). Moreover, a 2 hr BrdU pulse revealed that a fraction
of CD11b+Gr-1int and CD11b+Gr-1lo cells was already prolifer-
ating within the spleen of tumor-bearing mice at this early time
point (Figure 3B, right panel). Thus, it is likely that the chemother-
apeutic drugs found to share immune adjuvant properties in ourCelinitial screening are effective in reducing the expansion of highly
cyclingmyeloid cells. As expected, 5-FU reduced proliferation of
all the cell subsets when it was given 24–48 hr prior to the BrdU
pulse (data not shown); however, even if 5-FU given 28 days
earlier strongly affected the CD11b+Gr-1int cell numbers (Fig-
ure 3A), the percentage of BrdU+ cells in 5-FU treated animalsl Reports 2, 628–639, September 27, 2012 ª2012 The Authors 631
Figure 3. CD11b+Gr-1int Cells Comprise Highly Proliferating Myeloid Progenitors
(A) Kinetics of spleen repopulation of CD11b+Gr-1hi, CD11b+Gr-1int and CD11b+Gr-1lo cells after either 5-FU or PBS treatment. C57BL/6 mice were s.c. injected
with 1 3 106 MCA203 sarcoma cells in the right flank. After 3 hr, they were treated with a single dose of 5-FU. Mice were sacrificed at different times after
chemotherapy. Data are represented as mean ± SD (n = 3 mice) for each time point. Student’s t test is reported for day 30.
(B) Proliferative potential of myeloid cell subsets in either spleen (upper panels) or bone marrow (lower panels) was assessed by means of BrdU incorporation,
evaluated 48 hr (left panels) or 2 hr (right panels) after its in vivo inoculation. Data are represented as mean ± SE (n = 3 mice) of one representative experiment out
of two independently performed experiments.
(C) Splenic CD11b+ cells were FACS-sorted from the spleen of tumor-bearing mice and cultured for 4 days with GM-CSF (40 ng/ml) and IL-6 (40 ng/ml).
Representative dot-plot of one of three independent experiments.
(D) Adult CD45.2 C57BL/6 mice were injected with 1 3 106 syngeneic EL4 mouse thymoma cells. CD11b+Gr-1hi, CD11b+Gr-1int, CD11b+Gr-1lo, and CD11b+
Gr-1 cells were FACS-sorted from the spleens of tumor-bearing mice 2 weeks following implantation. Then 13 106 sorted cells were adoptively transferred to
adult CD45.1 C57BL/6 mice that had been implanted 1 week before with 1 3 106 EL4 cells. The phenotype of CD45.2 cells was analyzed 7 days after adoptive
transfer by flow cytometry. Representative dot-plots (n = 4 mice/group).
See also Figure S3.was not significantly altered within this cell population at such
a late time point (Figure 3B), suggesting that the few CD11b+
Gr-1int cells conserved their proliferative activity.
Proliferating hematopoietic stem cells and granulocyte/
macrophage progenitors were recently shown to accumulate
in the spleen of tumor-bearing mice (Cortez-Retamozo et al.,
2012). However, these progenitors do not express lineage
markers such as CD11b and Gr-1. Thus, we considered the
possibility that tumors could also cause the splenic expansion
of committed precursors with high proliferative potential.632 Cell Reports 2, 628–639, September 27, 2012 ª2012 The AuthorPurified splenic CD11b+Gr-1int cells are phenotypically homo-
geneous (i.e., they all express Ly6C and F4/80monocyte/macro-
phage markers), bear morphological features of both immature
myeloid cells (i.e., doughnut nuclei and CD117 expression;
Biermann et al., 1999; Ogawa et al., 1991) and Ly6ChiCCR2+
inflammatory monocytes (Geissmann et al., 2003), and strongly
suppress Ag-activated T lymphocytes (Figures S3Aand S3B).
To test the potential of this cell fraction to reconstitute the mye-
loid descendants, we isolated CD11b+Gr-1hi, CD11b+Gr-1int and
CD11b+Gr-1lo cells from the spleens of tumor-bearing mice ands
cultured themwith a combination of GM-CSF and IL-6, which we
previously demonstrated to be sufficient to generate in vitro
myeloid suppressors from bone marrow cells (Marigo et al.,
2010; Sonda et al., 2011). As shown in Figure 3C, only the
CD11b+Gr-1int fraction was able to give rise to all the other
CD11b+ myeloid subsets. Of more importance, when we fol-
lowed the fate of the same splenic cell subsets in vivo by using
congenic markers, after injection into tumor-bearing recipients,
only CD11b+Gr-1int cells displayed the broadest spectrum of
myeloid cell differentiation (Figure 3D). The same behavior could
also be observed when cells were transferred to and traced in
tumor-free mice (Figure S3C). Moreover, when CD11b+Gr-1hi,
CD11b+Gr-1int, and CD11b+Gr-1lo subsets were tested in a
colony-forming unit (CFU) assay, small round colonies, mainly
resembling CFU-M, could be detected only in CD11b+Gr-1int
agar cultures (Figure S3D). These observations led us to con-
clude that splenic CD11b+Gr-1int cells comprise a specific pop-
ulation of inflammatory monocytes with multipotent progenitor
features that, although partially committed, may contribute to
myeloid replenishment in the spleen during tumor growth.
A Tolerogenic Environment in the Marginal Zone of the
Spleen of Tumor-Bearing Hosts
When we performed immunostaining of the spleens for CD19
(lymphoid follicles rich in B cells), CD8 (T cell areas of white
pulp), and Ly6C (as amarker of CD11b+Gr-1int cells; Figure S4A),
we noticed that Ly6Chi myeloid cells were mostly distributed
within the marginal zone (MZ) and the outer layers of lymphoid
follicles (Figures S4A and S4B), which have been described as
the transit areas for memory CD8+ T cells during response to
infection (Khanna et al., 2007). The tumor induced an expansion
of Ly6C+ cells in the MZ, which appeared hyperplastic (Fig-
ure S4B, lower panel). Indeed, although B cell follicles accounted
for almost half of the spleen in tumor-free mice, their relative area
was strongly reduced in the spleens of tumor-bearing mice, due
to the accumulation of myeloid cells (Figure 4A). 5-FU adminis-
tration reestablished a normal cytoarchitecture in the spleens
of tumor-bearing hosts by reducing myeloid cell expansion and
consequently MZ hyperplasia. A cytofluorimetric analysis of
CD11b+Gr-1+ splenocytes confirmed the differences observed
by confocal microscopy (Figure 4B; Figure S4C).
Given the relevance of the CCR2 receptor in the inflammatory
monocyte egress from bone marrow and recruitment to periph-
eral tissues under several pathological conditions, including
tumor growth (Lesokhin et al., 2011, 2012; Leuschner et al.,
2011; Shi and Pamer, 2011), we speculated that it might also
play a role in the accumulation of Ly6C+ cells in the MZ of
the spleen. Of interest, when we analyzed spleen sections from
Ccr2/ and Ccl2/ mice, we observed a normal cytoarchitec-
ture and reduced myeloid accumulation despite the presence of
the tumor (Figures 4A and 4B; Figures S4B and S4C). CCR2
and CCL2 knockout phenocopied 5-FU treatment in terms of
both myeloid subset reduction and the ability to completely
abrogate the immunosuppressive influence exerted by the
splenic environment on Ag-specific CD8+ T lymphocyte prolifer-
ation (Figure 4C).
Spontaneous CCL2 production by whole splenocytes is
strongly increased in tumor-bearing mice, and isolated CD11b+Celcells clearly participate in the increase in chemokine production,
likely creating a positive feedback loop that enhances monocyte
recruitment to this organ (Figure 4D). Nestin-positive bone
marrowmesenchymal stem cells were recently shown to release
CCL2 rapidly in response to circulating toll-like receptor ligands
or bacterial infection, and cause inflammatory monocyte traf-
ficking from the bone marrow into the bloodstream (Shi et al.,
2011). In addition to myeloid Ly6C+ cells (Figure S4D), Nestin+
splenocytes (but not CD31+ endothelial cells) also express
CCL2 in the spleen of tumor-bearing hosts, as shown in Figure 4E
and Figure S4E. These cells were rarely detectable in the spleen
of tumor-free mice (not shown).
Splenic Immature Monocytes Cross-Present Tumor Ag
and Tolerize CD8+ T Lymphocytes
The relevant expansion of CD11b+Gr-1intLy6Chi cells in the
spleen makes a direct interplay with CD8+ T cells highly prob-
able, and indeed, recurrent contacts between these two cell
types were observed. In particular, we noticed that Ly6C+CD8+
T cells, which display a CD62L+CD44+CD127+CD25 T central
memory phenotype (TCM) and a strong cytotoxic activity (Fig-
ure S5A), are preferentially surrounded by Ly6C+ (monocytes)
rather than Ly6G+ (granulocytes) cells, in contrast to Ly6CCD8+
naı¨ve T lymphocytes (Figures 5A–5E; Figures S5B and S5C).
Memory CD8+ T lymphocytes could also be tracked as
CD11bGr-1intLy6Chi cells (Figure S5A; in these CD8+ T lympho-
cytes, Gr-1 expression is entirely due to the presence of the
Ly6C), and their percentages in the spleen were inversely related
to the percentages of CD11b+Gr-1intLy6Chi monocytes during
tumor development (Figures S2C, S2D and, S5D), suggesting
that these two cell types may interfere with each other for spleen
occupancy.We speculated that the prolonged and selective loss
of CD11b+Gr-1intLy6Chi cells in the spleen following 5-FU treat-
ment (Figure 3A) could be explained by the occupancy of the
MZ by drug-resistant Ly6C+Gr-1intCD8+ T cells, which are poorly
proliferating (Figure S5E) and thus are not likely affected by
a low-dose chemotherapy. Indeed, in Rag2/gc
/ immunode-
ficient mice, which lack B and T lymphocytes, myeloid cell
subsets were largely unaffected 30 days after 5-FU treatment,
in comparison with wild-type littermates (Figures S5F and S5G).
Moreover, when Ly6C+Gr-1intCD8+ T cells, but not CD4+ and
Ly6CCD8+ (naı¨ve) T cells, were transferred to tumor-bearing
Rag2/gc
/ recipients following low-dose chemotherapy, the
myeloid cell numbers were significantly reduced, highlighting
the role of memory CD8+ T lymphocytes in hampering myeloid
expansion and spleen replenishment (Figure 5F).
It has been suggested that splenic CD11b+Gr-1+ cells can
process and present tumor Ags (Kusmartsev et al., 2005). We
hypothesized that contacts between CD11b+Ly6Chi cells and
memory CD8+ T lymphocytes in the spleen could result in the
direct cross-presentation of tumor Ags in a tolerogenic manner.
Indeed, splenic CD11b+ cells isolated from OVA-EG7 tumor-
bearing mice initially primed OVA-specific CD8+ T lymphocytes
to proliferate in the absence of the exogenous peptide (Fig-
ure 5G, left panel), whereas CD11b+ splenocytes from mice
bearing the same tumor lacking OVA Ag (EL4) were inactive, indi-
cating that the proper OVA peptide was processed and pre-
sented. However, after the first stimulation by CD11b+ cells,l Reports 2, 628–639, September 27, 2012 ª2012 The Authors 633
Figure 4. The CCL2/CCR2 Axis Is Crucial for CD11b+Gr-1intLy6Chi Monocyte Recruitment to the Spleen
(A) Interfollicular area was calculated as the percentage of the whole spleen section by collecting 30 images from at least three different MCA203-bearingmice for
each of the indicated groups. Mean ± SD.
(B) Splenic distribution of myeloid subsets, determined by FACS staining of splenocytes for CD11b and Gr-1 markers in tumor-free and MCA203 tumor-bearing
mice from the indicated groups. Tumor-bearingmicewere sacrificed 25 days after tumor injection. Data represent mean ±SE of three separate experiments (n = 4
mice/group for each experiment). Comparisons among myeloid subsets from either tumor-free or MCA203 tumor-bearing mice were performed with Student’s
t test.
(C) CFSE-labeled, OVA-specific CD8+ T cells were cultured in the presence of splenocytes from the indicated experimental groups. Proliferation was compared
and normalized to MLPC setup with splenocytes from tumor-free mice. Data represent mean ± SE of three independent experiments (n = 3 mice/group for each
experiment). Statistical analysis was performed with Student’s t test.
(D) CCL2 release was measured in the supernatants of 48 hr cultures of either total or CD11b+-sorted splenocytes, isolated from either tumor-free or (MCA203,
EG7) tumor-bearing mice, by ELISA. Data are presented as mean ± SE of three independent experiments.
(E) Immunofluorescence was performed on thin spleen cryosections from MCA203 tumor-bearing mice. Scale bars are 50 mm. In the left panel, yellow arrows
point to Nestin+CCL2+ cells and white arrows point to Ly6C+CCL2+ cells. In the right panel, arrowheads point to CD31+CCL2 cells.
See also Figure S4.the same OVA-specific T lymphocytes were no longer able to
respond to the cognate Ag upon restimulation with the Ag
presented by Ag-presenting cells (Figure 5G, right panel).
We observed that cross-presentation and tolerance induction
involved, at least partially, the uptake of tumor Ags from blood
circulating exosomes, as the exosome inhibitor dimethyl-amilor-
ide (DMA) (Chalmin et al., 2010) was shown to limit the extent of
both cross-presentation and tolerancewhen administered in vivo
to tumor-bearing mice. Intriguingly, Ag cross-presentation and
consequently cross-tolerance were abrogated in Ccr2/ mice,
indicating that splenic CD11b+CCR2+ myeloid cells are respon-
sible for cross-tolerization of peripheral CTLs (Figure 5G). This
functional behavior was fully mirrored by the ability of splenic
CD11b+ cells to cross-present tumor-derived OVA peptide on
MHC I class molecules on their surface, since either DMA treat-
ment or CCR2 deficiency strongly impaired Ag presentation (Fig-634 Cell Reports 2, 628–639, September 27, 2012 ª2012 The Authorure 5H). CD11b+Gr-1intLy6ChiCCR2+ monocytes positive for
MHC I-OVA peptide complexes were also detected among
tumor-infiltrating leukocytes, but were not observed in tumor-
draining lymph nodes, bone marrow, or blood (data not shown).
The splenectomy experiments described above thus indicate
that even if tumor Ag presentation occurs within the tumor envi-
ronment, it is not sufficient to induce Ag-specific tolerance.
CCL2 Serum Levels Are Predictive of the Clinical
Outcome in Patients Responding to Cancer Vaccination
UsingCcl2/mice, we noticed that CCL2 deficiency helped the
endogenous immune response to eradicate tumor cells exclu-
sively when mice were implanted with highly antigenic tumor
cells, as in the case of 4T1-HA mammary carcinoma (Figure 6A).
To investigate whether this observation could be relevant for
clinical purposes, we assessed CCL2 serum levels in patientss
Figure 5. Splenic CD11b+Ly6Chi Monocytes Are in Close Contact with and Cross-Present Tumor Ags to CD8+ T Cells
(A–D) Distribution of Ly6C+CD8+ (memory T lymphocytes), Ly6C+CD8 (monocytes), and Ly6CCD8+ (naı¨ve T lymphocytes) cells in the spleen ofMCA203 tumor-
bearing mice. White arrows point to Ly6C+CD8+ cells, yellow arrows point to Ly6C+CD8 cells, and pink arrowheads point to Ly6C+myeloid cells. Scale bars are
50 mm for (A) and (C), and 25 mm for (B) and (D).
(E) The numbers of Ly6C+Ly6GCD8 (green bars), Ly6C+/Ly6G+CD8 (blue bars), and Ly6CLy6GCD8+ (red bars) cells surrounding either Ly6C+CD8+ or
Ly6CCD8+ lymphocytes were calculated as described in Figure S5B. Data are presented as mean ± SE (n = 70 cells/group). Statistical analysis was performed
with Student’s t test.
(F) Rag2/gc
/ mice were s.c. implanted with MCA203 sarcoma cells and after 3 hr were treated with a single dose of 5-FU. After 2 days, 106 of CD8+Ly6C+,
CD8+Ly6C, or CD4+ T cells were injected i.v. in the same mice. Rag2/gc
/ mice were sacrificed at different time points after chemotherapeutic treatment.
Statistical analysis was performed with Student’s t test; p values for the comparison between MCA203 + 5-FU and MCA203 + 5FU + CD8+Ly6C+ groups on day
21 are shown.
(G) CD11b+ cells were isolated from the spleen of either wild-type orCcr2/ EG7 or EL4 tumor-bearingmice and cultured for 3 days together with CFSE-labeled,
OVA-specific CD8+ T cells (left panel) in the absence of exogenous peptide. The values reported refer to cultures with 24% CD11b+ cells on total cell counts.
When required, mice received daily i.p. injection of DMA for 1 week before sacrifice. OVA-specific CD8+ T cell proliferation, measured by CFSE dilution, was
normalized to the values obtained in the presence of OVA peptide-pulsed feeder cells (ctrl). Lymphocytes from the former cultures were restimulated with Ag-
pulsed feeder cells (right panel), and CFSE dilution was measured 3 days after the second stimulation. OVA-specific CD8+ T cell proliferation was normalized to
the values obtained in control cultures. Data represent mean ± SE of three independent experiments (n = 3 mice/group for each experiment). Statistical analysis
for the indicated comparisons was performed with Student’s t test.
(H)MHC class I-OVA complexes were labeled on splenic CD11b+ cells used in the previous cultures. Data represent mean ±SE of three independent experiments
(n = 3 mice/group for each experiment). Statistical analysis for the indicated comparisons was performed with Student’s t test.
See also Figure S5.who had undergone active immunotherapy. We considered
patients with renal cell carcinoma (RCC) and colorectal cancer
(CRC) who were enrolled in phase I/II studies and had received
two therapeutic vaccines, IMA901 and IMA910, respectively,
which consist of naturally presented tumor-associated peptidesCel(TUMAPs; Walter et al., 2012). In these trials, CCL2 serum levels
measured prior to vaccination were used to classify the patients
into two subgroups. There was no difference in the number
of multipeptide immune responders versus nonresponders
among patients with either low or high CCL2 serum levels. Inl Reports 2, 628–639, September 27, 2012 ª2012 The Authors 635
Figure 6. CCL2 Serum Levels Correlate with
Myeloid Cell Accumulation and Response
to Immunotherapy in Renal Cell and Colo-
rectal Cancer Patients
(A) BALB/c (left panel) orCcl2/ (right panel) mice
were subcutaneously injected with either 4T1 or
4T1-HA cell lines. Mice survival (n = 12 mice/
group) was analyzed by means of the Kaplan-
Meier method.
(B) Combined analysis of OS in RCC and CRC
patients of two immunotherapy trials with multi-
peptide vaccines. Shown is a survival analysis
of immune- and CCL2-evaluable patients without
(left panel, n = 88) or with (right panel, n = 48)
vaccine-induced multipeptide responses, group-
ed by CCL2 levels above (solid line) or below
(dashed line) the median value.
(C) Spearman’s rank correlation analysis of serum
CCL2 and LinHLA-DRCD33+ myeloid cell levels
among PBMCs, determined prior to immuno-
therapy, in individual RCC patients (d represents
individual patients, n = 58).
See also Figure S6 and Table S1.agreement with our preclinical results, however, only in patients
who developed multiple T cell responses to peptide vaccination
were high CCL2 serum levels predictive of worse prognosis in
terms of OS (Figure 6B). Pretreatment levels of distinct subsets
of myeloid cells were significantly increased in the blood of
these patients relative to healthy controls (Walter et al., 2012).
Of interest, we observed that, at least in the patients with
RCC, CCL2 serum levels directly correlated with peripheral
blood mononuclear cell (PBMC) frequencies of an immature
LinHLA-DRCD33+ myeloid cell subset (Figure 6C), which
was recently described as highly proliferating, strongly immuno-
suppressive, and predictive of disease progression in CRC and
breast cancer (Solito et al., 2011). Correlations of pretreatment
CCL2 serum levels with other human myelomonocytic cell
subsets were less robust (Figure S6; Table S1).
DISCUSSION
It has recently become clear that the immune system has a
crucial role in modulating tumor progression and response to636 Cell Reports 2, 628–639, September 27, 2012 ª2012 The Authorstherapy. Numerous anticancer agents
that were used in the past for their
cytotoxic properties can modulate the
host immune system, and sometimes
induce a long-term protective memory
T cell response. We unveiled a previ-
ously unknown environment in the MZ of
the spleen of tumor-bearing hosts in
which immunoregulatory monocytes co-
exist with memory CD8+ T cells. These
multipotent inflammatory monocytes are
recruited to the MZ by CCL2 and cross-
tolerize Ag-specific lymphocytes, at
least in part by sampling tumor-releasedexosomes. Because of the high proliferative rate of these
monocytes, some chemotherapeutic agents are very active in
depleting them while sparing poorly proliferating lymphocytes,
and the subsequent occupation of the splenic environment by
CD8+ T cells hampers the replenishment of myeloid cells fol-
lowing chemotherapy. The contribution of both depletion of
regulatory T lymphocytes and induction of immunogenic cancer
cell death by chemotherapy to the described phenomena was
negligible. These findings provide a rational explanation for the
often empirical and paradoxical observation that chemotherapy
is one of the most effective adjuvants for ACT, and suggest that
an extensive lympho-myeloablation before ACT is likely unnec-
essary or even detrimental. We propose that our findings lay
the foundation for defining both the dose and class of chemo-
therapeutic agents that will have the greatest impact on ACT.
Our data depict two scenarios for future approaches aimed
at enhancing ACT therapeutic impact. First, metronomic che-
motherapy treatment could be exploited to maintain a long-
term contraction of the immunosuppressive monocyte expan-
sion. Metronomic chemotherapy was originally developed to
overcome drug resistance; however, low-dose cyclophos-
phomide was reported to limit regulatory T lymphocytes and
increase innate immune response (Ghiringhelli et al., 2004; Ghir-
inghelli et al., 2007). Second, chemotherapeutic drugs with
distinct immunomodulatory properties could be combined with
cancer immunotherapy. As recently reviewed, in fact, some
agents can induce immunogenic cancer-cell death (Galluzzi
et al., 2012; Zitvogel et al., 2011). Of interest, many of the drugs
that alter the splenic immunoregulatory environment do not
affect the immunogenic context of cancer death. Future devel-
opments could thus be based on optimizing low-dose che-
motherapy to eliminate immunosuppressive monocytes before
administering a specific drug that is able to elicit immunogenic
death and increase tumor-Ag uptake by APCs present in the
tumor microenvironment.
A prediction based on our data is that adoptive transfer of Ag-
specific CD8+ TCMwould be the best choice for passive immuno-
therapy, because these cells may be able to interfere with
myeloid cell expansion in the spleen following chemotherapy.
Indeed, this hypothesis is supported by some published experi-
mental data showing that adoptively transferred CD8+ TCM were
more potent than effector memory CD8+ T cells specific for
a melanoma Ag in causing the eradication of large established
tumors (Klebanoff et al., 2005). Of interest, this greater efficacy
achieved with CD8+ TCM was related to the ability of tumor-reac-
tive T cells to traffic better to secondary lymphoid organs than to
tumor sites (Klebanoff et al., 2005).
Inmouse studies, a relationship between the extent of lympho-
and myelodepletion and the magnitude of the in vivo antitumor
effect of the transferred cells seemed to emerge (Wrzesinski
et al., 2010; Wrzesinski and Restifo, 2005). However, our data
suggest that myeloablative chemotherapymay not be necessary
for an optimal adjuvant activity of ACT. In the case of 5-FU,
for example, relatively low doses of drugs were administered
(40mg/kg versus 100mg/kg, which is commonly used in precon-
ditioning regimens). On the basis of our data, we can hypothe-
size that high-dose chemotherapy can be either detrimental or
beneficial depending on its prevailing effects on the myeloid or
lymphoid compartment.
CCL2 has multiple roles in cancer progression. Gr-1+ inflam-
matory monocytes were not found at primary mammary tumor
lesions, and instead were preferentially recruited by CCL2 to
pulmonary metastases to assist tumor spreading. Moreover,
CCL2 expression and macrophage infiltration were shown to
correlate with poor prognosis and metastatic disease in human
breast cancer (Qian et al., 2011). Recent evidence, however,
shows that the antitumor effects of CCL2 blockade in vivo are
dependent on the host immune system. In fact, administration
of anti-CCL2 monoclonal antibody (mAb) induced tumor-spe-
cific CD8+ T cell activation and expansion rather than a decrease
in the number of tumor-associated macrophages (Fridlender
et al., 2010, 2011). Moreover, the antitumor effects of CCL2
blockade was completely lost in immunodeficient mice or after
CD8+ T cell depletion, clearly enforcing the concept that CCL2
blockade reestablishes the immune response in the tumor-
bearing host, in similarity to the data we obtained with either
5-FU administration or ccl2/ccr2 gene knockout ablation. More-
over, we show here that CCL2 serum levels correlate with theCelexpansion of immature myeloid cells in the blood of cancer
patients, and, more importantly, with the clinical response to
cancer vaccination in patients who develop broad immune
responses to the tumor Ags present in the vaccine. The spleen
is not easily accessible in patients, but our findings indicate
that blood may be used to provide information relevant for the
clinical outcomes of cancer immunotherapy.EXPERIMENTAL PROCEDURES
Splenectomy
The abdominal cavity of mice under general anesthesia (Rompum and Zoletil)
was opened and the spleen vessels were cauterized. The spleen was carefully
removed and placed in cold phosphate-buffered saline (PBS) solution. For
control experiments, the abdomen was opened but the spleen was not
removed (sham surgery).In Vivo Tolerance Assay
C57BL/6 mice were either splenectomized or subjected to sham surgery. After
10 days, 0.53 106 EG7 cells were injected subcutaneously (s.c.) into the flank
of CD45.2+mice. Seven days later, the mice were adoptively transferred with 2
3 107 splenocytes derived from OT-1 transgenic mice (CD45.1+), correspond-
ing approximately to 5 3 106 OVA-specific CD8+ T cells. Two weeks after
tumor injection, the animals were euthanized and cells from lymph nodes
and spleens were tested by ELISpot and intracytoplasmic cytokine staining
(ICS) as previously described (Dolcetti et al., 2010a, 2010b; Marigo et al.,
2010). Where indicated, tumor-bearing mice were s.c. vaccinated with 1 3
106 OVA257-264 peptide-pulsed DCs 2 days post lymphocyte transfer (Dolcetti
et al., 2010a). When Ag-experienced CD8+ T cells were adoptively transferred,
OT-1 splenocytes were cultured with the cognate peptide and 20 U/ml IL-2 for
5 days (>97% CD8+ cells after stimulation). Similar experiments were per-
formed on a BALB/c background, with s.c. injection of 1 3 106 4T1-HA tumor
cells 10 days after surgery. After 20 days, the mice were transferred with 2 3
107 splenocytes derived from CL4 mice and were vaccinated with 1 3 106
HA512-520-peptide pulsed DCs 2 days after ACT. The mice were sacrificed at
day 26 and lymph nodes were stimulated as previously described.ACT
ACT in mouse transplantable tumor models was performed in Rag2/gc
/
and C57BL/6 mice after subcutaneous challenge with 1 3 106 tumor
cells. When the tumor volume was 200 mm3, the mice were treated with
40 mg/kg 5-FU. After 3 days, 5 3 106 Ag-specific CTLs were intravenously
(i.v.) injected. At the time of CTL transfer, mice were intramuscularly (i.m.)
injected with 5 3 108 PFU of a recombinant adenoviral vector coding for the
relevant Ag recognized by transferred T cells and then intraperitoneally (i.p.)
treated with 30,000 IU rIL-2 twice a day for 3 consecutive days. Blindmeasure-
ments of tumor mass were carried out with the use of digital calipers. Mice
were euthanized when the tumor volume reached 1,000 mm3. In some exper-
iments, OVA-specific CD8+ T cells were administered to EG7-bearing recipi-
ents, as described previously (Molon et al., 2011).Cell Isolation
CD11b+Gr-1hi and CD11b+Gr-1int cells were isolated with the use of Miltenyi
Biotec antibodies and microbeads as previously described (Dolcetti et al.,
2010a, 2010b). The purity of cell populations was evaluated by flow cytometry
and exceeded 90%. For fluorescence-activated cell sorting (FACS) sorting,
splenocytes were labeled with PERCP-Cy5.5 anti-CD11b and APC anti-Gr-1
mAb, and sorted to >98% purity with a FACSAria (BD) flow cytometer.Cytotoxicity Assay
After 5 days, the cultures were tested for the ability to lyse an allogenic target
(MLR) or target cells pulsed with a specific peptide (MLPC) in a 5 hr 51Cr-
release assay as previously described (Dolcetti et al., 2010a).l Reports 2, 628–639, September 27, 2012 ª2012 The Authors 637
In Vitro Cross-Tolerance Assay
To evaluate myeloid-induced tolerance, CD11b+ cells were immunomagneti-
cally sorted from the spleens of EG7- or EL4-bearing mice and cultured,
ranging from 24% to 3% of the whole culture, together with C57BL/6 and car-
boxyfluorescein succinimidyl ester (CFSE)-pulsed 1% OVA-specific spleno-
cytes. OVA257-264 peptide was added only to control cultures. After 3 days,
proliferation was assessed by CFSE dilution in half of the cultures, and CTLs
were recovered from the remaining cultures and plated with peptide-pulsed
splenocytes for another 3 days. After 6 days from the initial culture, CFSE
dilution was assessed in restimulated CTLs to evaluate the induction of toler-
ance. When required, EG7-tumor-bearing mice received daily i.p. injection of
1 mmol/kg DMA (Sigma-Aldrich) for 1 week before they were sacrificed.
Phase II Study of IMA901 in Renal Cell Cancer
IMA901 (Walter et al., 2012) is a therapeutic cancer vaccine based on the
selection of naturally presented TUMAPs (nine HLA-A*02 and one HLA-DR
binding). In the multicenter phase II study IMA901-202, 68 HLA-A*02-positive
patients (intent-to-treat [ITT] group) with advanced clear-cell type RCC and
documented progression during or after standard first-line therapy were
randomized 1:1 to receive up to 17 intradermal vaccinations of IMA901 over
9 months, together with 75 mg granulocyte-macrophage colony-stimulating
factor (GM-CSF) plus/minus a single infusion of cyclophosphamide (CY;
300 mg/m2) 3 days before the first vaccination. A total of 64 patients were
treated per protocol (PP). Blood for PBMCs isolation was collected at
day 3, 1, 15, 22, and 36 relative to the first vaccination. Blood for serum
analysis was collected at day 3.
Phase I/II Study of IMA910 in Colorectal Cancer
IMA910 is a peptide-based vaccine consisting of 10 HLA-A*02 binding and
three HLA-DR binding TUMAPs presented on colorectal tumors and overex-
pressed relative to healthy tissues. The multicenter clinical phase I/II study
IMA910-101 enrolled 92 HLA-A*02 ITT patients with advanced/metastatic
CRC who were at least clinically stable after 12 weeks of first-line oxalipla-
tin-based therapy. The patients were infused with a single dose of CY
(300 mg/m2) 3 days prior to first vaccination and thereafter were repeatedly
immunized intradermally (up to 16 vaccinations over 8 months) with IMA910
in combination with GM-CSF (75 mg, cohort 1; n = 66) or, in a second cohort,
with GM-CSF plus topically applied imiquimod (23 12.5 mg, cohort 2; n = 26)
as an additional adjuvant. A total of 82 patients were treated PP. Blood for
PBMC isolation was collected at days 3, 1, 8, 15, 22, 36, and 57 relative to
the first vaccination. Blood for serum analysis was collected at days42 to4.
Both clinical studies (IMA901-202 and IMA910-101) were conducted in
accordance with the Declaration of Helsinki, current International Conference
on Harmonisation of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use (ICH) guidelines, and all applicable regulatory and ethical
requirements. Approvals by the relevant Institutional Review Boards were
given and all subjects provided written informed consent before study-related
procedures were performed.
Statistics
A two-tailed Student’s t test orWilcoxon’s test was used to compare data sets,
with an a-level of 0.05 (in the figures, significance is indicated as * p % 0.05,
** p%0.01, and *** p%0.001). AKaplan-Meier survival analysiswasperformed
for the comparison of survival curves. An unpaired, two-sided Welch’s t test
was used to test the association of serum CCL2 levels with T cell responses
in both clinical trials. Because CCL2 was measured using different assays in
both trials, differences between RCC and CRC CCL2 serum values may be
due to differences in serum levels between the two diseases, or to differences
between the two assays. To assess the influence ofCCL2 serum levels onOS in
a combined analysis of RCC and CRC patients (PP populations), we dichoto-
mized continuous serum levels within each tumor entity by cutting at the
medians of the respective ITT populations (median CCL2 RCC 396.5 pg/ml,
CRC 1196.6 pg/ml) and assigning every patient to the CCL2low or CCL2high
subgroup. We performed OS analyses using R (GNU) programming language
version 2.14.2 with the ‘‘coin’’ package. We conducted a stratified log-rank
test to assess the difference in OS between CCL2low and CCL2high patients
using surv_test. Each trial (RCC or CRC) was included as a stratification638 Cell Reports 2, 628–639, September 27, 2012 ª2012 The Authorfactor to calculate the p values within multipeptide-responders and nonmulti-
peptide responders (PP). The correlation between CCL2 and MDSC levels
was analyzed with Spearman’s rank correlation. Kaplan-Meier curves and
correlation analyses were generated with GraphPad Prism 5 software.
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